Watson Unithroid promotions
Executive Summary
Watson is mailing marketing literature to managed care organizations as part of a new promotional campaign for Unithroid (levothyroxine). FDA's call for Abbott to reduce Synthroid production gradually until the drug is approved prompted increased Watson focus on the managed care sector (1"The Pink Sheet" July 16, p. 16). The company particularly hopes to attract mid-sized organizations who are most likely to be impacted by the Synthroid phase-out